Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neural TherapeuticsFRA:M6B FCF Yield % is -24.08 as of Jul. 24, 2026. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Neural Therapeutics ranks worse than 69.48% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Neural Therapeutics FCF Yield % Related Terms
Neural Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Neural Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M6B vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Neural Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neural Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neural Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Neural Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neural Therapeutics (FRA:M6B) has a FCF Yield % of -24.08 as of Jul. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #979 out of 1409 companies in the Biotechnology industry, placing it in the top 69.5%.
Is Neural Therapeutics' FCF Yield % too high?
Neural Therapeutics' current FCF Yield % is -24.08. Based on the distribution chart, Neural Therapeutics ranks #979 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint.
How does Neural Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #979 out of 1409 companies for FCF Yield %. This places Neural Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current FCF Yield % is -24.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current FCF Yield % of -24.08. The current FCF Yield % is -24.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current FCF Yield % is -24.08 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M6B has been successfully added to your 
